Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection

Research output: Contribution to journalArticle


BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P

Original languageEnglish
Pages (from-to)1341-1344
Number of pages4
Issue number10
Publication statusPublished - May 2007



  • Hepatitis B virus
  • Hepatitis delta virus
  • Lamivudine
  • Liver transplantation
  • Outcome

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this